INSUBCONTINENT EXCLUSIVE:
NEW DELHI: Shares of Cadila Healthcare gained nearly 2 per cent in Monday's trade after the company received final approval from the USFDA
to market Doxycycline Hyclate capsules USP, antibiotic used for treating bacterial infections.
The company which develops, manufactures and
markets a broad range of healthcare therapies said that the capsules will be manufactured at the Zydus Cadila group's manufacturing
facility at SEZ, Ahmedabad
Following the announcement, the stock rose 1.71 per cent to hit a high of Rs 359.85 on BSE
"Zydus Cadila has received the final approval from the USFDA to market Doxycycline Hyclate Capsules USP, 50 mg and 100 mg," the company
said in a regulatory filing
It is a tetracycline antibiotic used for the treatment of a wide variety of bacterial infections, including those that cause acne
This medication is also used for prophylaxis of malaria," the filing said
The group has more than 195 approvals so far.
